Paris-based healthtech startup Biolevate has raised €6 million in a Seed funding round led by EQT Ventures, aiming to transform the labor-intensive process of medical writing in the biotech industry. The company's innovative platform leverages natural language processing (NLP) and visual document reading to assist medical writers, reducing the time and effort required to create high-quality documentation.

The need for efficient medical writing is pressing, as the biotech industry continues to rely heavily on manual documentation processes. Despite advancements in AI-assisted drug development, the industry still struggles with creating and managing research and compliance documents, posing a significant administrative burden on pharmaceutical companies. Biolevate's platform addresses this challenge by optimizing the creation and management of these documents, using NLP and computer vision to guide writers through the materials.

Co-founders Joel Belafa and Nathan Chen, who have been friends for 25 years, drew on their respective expertise in AI for enterprises and pharmaceutical processes to develop the platform. Belafa, who was employee number 20 at French AI unicorn Dataiku, and Chen, who learned about pharmaceutical processes at Danish healthcare company Coloplast, launched their first prototype, Elise, which caught the attention of Anas Laaroussi and Antoine De Torcy, who joined as CTO and CPO, respectively.

Biolevate's platform has already gained recognition, with the company recently making Station F's Future 40 list. The Seed funding will enable the company to further develop its platform, which has the potential to transform medical documentation processes into a seamless and effective procedure that supports innovation and drives scientific breakthroughs benefiting society, according to Julien Hobeika, Partner at EQT Ventures.

In the event that the strategy in its current form does not work, Belafa outlined alternative plans, including commercializing the platform as a service for other industries, selling individual models as an API, or using it to offer a drug discovery professional service. This flexibility underscores Biolevate's commitment to harnessing AI to drive efficiency and innovation in the biotech industry.

As the biotech industry continues to evolve, Biolevate's AI-powered platform is poised to play a critical role in streamlining medical writing, enabling pharmaceutical companies to focus on what matters most – developing life-changing treatments. With this €6 million Seed funding, Biolevate is well-positioned to drive meaningful change in the industry and improve patient outcomes.